Search Results
Your search for ,twO matches 12381 pages
Showing 9501 - 9550FOXP3 Expression Linked to Better Survival with Adjuvant Anthracycline Not Followed by Taxane in Breast Cancer
The French UNICANCER-PACS 01 trial compared six cycles of anthracycline-based adjuvant therapy with FEC (epirubicin, cyclophosphamide, fluorouracil; FEC6) vs three cycles of FEC followed by three cycles of docetaxel (FEC/docetaxel) in patients with node-positive primary breast cancer. After...
Role of Sentinel Node Surgery Explored in Node-positive Breast Cancer
Sentinel lymph node surgery performed after neoadjuvant chemotherapy in women presenting with node-positive disease could spare many patients with breast cancer needless axillary lymph node dissection, according to a study of the American College of Surgeons Oncology Group presented at the 2012 San ...
Evaluating HER2 Status in Esophageal Cancers: FISH vs Immunohistochemistry
In screening patients with esophageal cancers for HER2 status, the relative efficiency of immunohistochemistry (IHC) vs fluorescence in situ hybridization (FISH) has been debated. Researchers from the Mayo Clinic compared the testing strategies and have proposed an algorithm that puts IHC up front, ...
Finding New Strategies to More Effectively Treat Pancreatic Cancer
While some progress has been made in understanding the molecular pathogenesis, genetic risk factors, and genomics of pancreatic adenocarcinoma, the disease remains one of the most challenging malignancies. According to Surveillance, Epidemiology, and End Results (SEER) figures, 44,000 people were...
ASCO International Expands to Improve Cancer Care Worldwide
As a global community of cancer care providers in more than 100 countries around the world, ASCO is uniquely positioned to improve cancer patient outcomes worldwide—an opportunity that it has seized since the organization’s inception through numerous innovative programs. Building upon this...
Expert Point of View: Nasser H. Hanna, MD
In an accompanying editorial, Nasser H. Hanna, MD, of Indiana University, Indianapolis, suggested that although the question of two chemotherapy drugs vs one in this setting made sense at the time GOIRC 02-2006 was initiated, advances in understanding of the heterogeneity of non–small cell lung...
Cytarabine in Conditioning Regimen for Younger Patients with MCL
High-dose cytarabine should be incorporated into the induction regimen of younger patients with mantle cell lymphoma (MCL) before autologous stem cell transplantation, according to final results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network, presented at the ASH Annual...
Quizartinib Data Encouraging in Phase II Investigations of FLT3 Mutation–positive Acute Myeloid Leukemia
The investigational oral FLT3 inhibitor quizartinib appears to be a safe and effective treatment for patients with relapsed or refractory acute myeloid leukemia (AML), according to results of a phase II trial presented at the 54th Annual Meeting of the American Society of Hematology (ASH) in...
Expert Point of View: Martin Dreyling, MD
“The BRIGHT study had a noninferiority design, but I question why BR was not found superior, because the StiL trial showed a huge difference in progression-free survival favoring BR,” said Martin Dreyling, MD, Professor at the University of Munich in Germany. “In BRIGHT, BR achieved higher...
Bendamustine/Rituximab Noninferior to Standard Chemotherapy for Advanced Indolent Non-Hodgkin and Mantle Cell Lymphomas
The combination of bendamustine (Treanda) and rituximab (Rituxan), or BR, was found to be noninferior to commonly used chemotherapy with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) in...
Pomalidomide in Previously Treated Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On February 8, 2013, the immunomodulatory agent...
Obesity, Physical Inactivity Linked with Risk for Subtype of Colorectal Cancer
An increasing body mass index (BMI) was associated with a higher risk for colorectal cancer with a specific molecular characteristic, and inversely, physical activity was linked to a decreased risk for that same cancer, according to data published in Cancer Research,1 a journal of the American...
Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from FDA
Janssen Research & Development, LLC, and Pharmacyclics, LLC, announced that the FDA has granted Breakthrough Therapy Designations for the investigational oral agent ibrutinib as a monotherapy for two B-cell malignancies: in patients with relapsed or refractory mantle cell lymphoma who have...
Colorectal Cancer: A Decade of Progress
The 2013 Gastrointestinal Cancers Symposium marked the 10th anniversary of the meeting. Richard M. Goldberg, MD, the Klotz Family Chair in Cancer Research, Professor of Medicine, and James Cancer Hospital Physician-in-Chief at The Ohio State University, looked back over the decade to highlight the...
Expert Point of View: William K. Oh, MD
Formal discussant William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, Professor of Medicine and Urology, and the Ezra M. Greenspan, MD, Professor in Clinical Cancer Therapeutics at Icahn School of Medicine at Mount Sinai, New York, was not convinced that corticosteroids...
Expert Point of View: Anthony D’Amico, MD
Now there are mature data from three trials comparing adjuvant radiotherapy vs a wait-and see approach in men following radical prostatectomy, said formal discussant Anthony D’Amico, MD, Dana-Farber Cancer Center and Harvard Medical School, Boston, at the Genitourinary Cancers Symposium. Despite...
Reduced Risk of PSA Failure with Adjuvant Radiotherapy vs Wait-and-see Approach in Stage T3 Prostate Cancer
Extended follow-up of the German ARO 96-02 trial shows that adjuvant radiotherapy reduces the risk of biochemical failure in men whose prostate cancer extends through the prostate capsule (stage T3), compared with a wait-and-see approach, after radical prostatectomy. Adjuvant radiotherapy reduced...
Two Studies Focus on Treatment Strategies for Preserving the Larynx While Increasing Survival
Two recent studies in the Journal of Clinical Oncology focused on treatment strategies to preserve the larynx while increasing survival of patients with cancer of larynx. RTOG 91-11 Ten-year results from the Radiation Therapy Oncology Group (RTOG) 91-11 trial found that both chemotherapy regimens...
Number of Cancer Survivors Expected to Increase to 18 Million by 2022
The American Association for Cancer Research recently released its second Annual Report on Cancer Survivorship in the United States. The report shows that as of January 2012, there were approximately 13.7 million cancer survivors in the United States, a number that is expected to rise by 31% to 18...
Flaxseed
Dietary supplement use by patients with cancer has increased significantly over the past 2 decades despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and the...
Barrie R. Cassileth, MS, PhD, Champion of Integrative Oncology, Continues to Nurture Growth of the Field
Over the past decade, integrative oncology has gained wide acceptance as an evidenced-based way to improve the lives of patients with cancer throughout the continuum of their care. The ASCO Post recently spoke with Barrie R. Cassileth, MS, PhD, Chief of the Integrative Medicine Service and Laurance ...
Recently Reported Long-term Outcomes Could Motivate More Men with Prostate Cancer to Consider Active Surveillance
Fifteen years after being treated with radical prostatectomy or external-beam radiation for localized prostate cancer, “the prevalence of erectile dysfunction was nearly universal,” among men enrolled in a long-term functional outcomes analysis of the Prostate Cancer Outcomes Study (PCOS). There...
Radiation, Still Misunderstood after All These Years
Over the past few decades, radiation therapies have rapidly advanced, due, in large part, to an increasing technologic armamentarium. Among modern science’s most impressive machines, for example, 220-ton particle accelerators can generate near-light-speed beams of protons, with sniper-like...
Majority of Ovarian Cancer Patients Do Not Receive Recommended Treatment, Study Shows
Women are 30% less likely to die of ovarian cancer if they have guideline-recommended treatment, yet nearly two-thirds of those with the disease do not receive it, often because they are cared for at hospitals that treat a small number of ovarian cancer patients. These are the findings of a study...
Intraperitoneal Chemotherapy Gives Ovarian Cancer Patients Better Chance of Survival
Patients with advanced ovarian cancer who undergo intensive treatment with chemotherapy that bathes the abdomen are significantly more likely to live longer than those who receive standard intravenous (IV) chemotherapy, according to a study that analyzed long-term follow-up from two landmark...
Oncology Meetings
April IV Latin American Symposium of Gastroenterology OncologyApril 17-20 • Vina del Mar, ChileFor more information: www.slago.com 3rd ITLT Essen 2013 - Interdisciplinary Treatment of Liver TumorsApril 18-20 • Essen, GermanyFor more information: www.itlt.org The Arizona Clinical Oncology Society...
Effects of Menarche and Menopause on Breast Cancer Risk: Meta-analysis Findings
Menarche and menopause mark the onset and offset of ovarian and endocrine activity associated with reproduction, and early menarche and late menopause are known to increase risk of breast cancer. In a recent Lancet Oncology article, the Collaborative Group on Hormonal Factors in Breast Cancer...
New ACCC Officers and Trustees
Results of the election of new officers and trustees (2013–2014) for the Association of Community Cancer Centers (ACCC) were announced recently at the ACCC Annual National Meeting. First Nonphysician ACCC President Elected Virginia Vaitones, MSW, became ACCC President at the 39th Annual National...
SIDEBAR: Further Reflections on a Successful Trial
The authors are to be congratulated for successfully conducting a randomized study of FLAG (fludarabine, cytarabine, and granulocyte colony-stimulating factor [Neupogen]) vs FLAG plus liposomal daunorubicin (DaunoXome) in relapsed pediatric acute myeloid leukemia (AML). The difficulty in conducting ...
Addition of Liposomal Daunorubicin Improves Early Outcome in Patients with Pediatric Relapsed AML
Optimal reinduction therapy for patients with relapsed pediatric acute myeloid leukemia (AML) remains undefined. Liposomal daunorubicin (DaunoXome), which offers the potential for reduced cardiotoxicity compared with traditional daunorubicin, is effective in this setting. Gertjan J.L. Kaspers, MD,...
Qigong Practice Associated with Quality-of-life Benefits in Women Undergoing Radiation Therapy for Breast Cancer
Qigong (“qi” or “chi” = energy flow, “gong” = skill or achievement) is an integrated mind-body exercise and meditative practice that involves rhythmic breathing coordinated with repetition of fluid movements and calm focus on the body. A study reported in Cancer by Zhen Chen, MD, and colleagues...
Pilot Study Seeks to Offer Social Support to Patients with Mesothelioma
Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reported that group therapy sessions may help patients cope with mesothelioma. Their two-part pilot study, which began recruitment in May 2011, is examining the emotional burden of the cancer and offers discussion groups as a source of...
Tobacco Cessation Treatment Needed in Routine Cancer Care
Researchers at Memorial Sloan-Kettering Cancer Center reported that a new behavioral tapering intervention combined with cessation counseling and pharmacotherapy did not affect short- and long-term abstinence rates compared to cessation counseling and pharmacotherapy alone among smokers newly...
SIDEBAR: APOS Best Program Award
This poster by Ms. Zadeh and colleagues was one of two tied for the Best Program award, presented by the APOS Scientific Program Committee at the Annual Meeting. The two award-winning posters were: Helping Providers to Help Adolescents and Young Adults be Involved in End-of-life Care: The...
Highlights of ACCC Annual Meeting Include Discussion of Trends Shaping the Future of Health Care
The 39th Annual National Meeting of the Association of Community Cancer Centers (ACCC) was held in Washington, DC, in March. With a focus on business, economics, and policy, the program included the inauguration of a new ACCC President (see page 102), a keynote speech on the future of health care,...
Implementing a National Cancer Clinical Trials System for the 21st Century
In March 2011, the National Cancer Policy Forum of the Institute of Medicine (IOM), in conjunction with ASCO, held a workshop to discuss a collaborative approach to making the National Cancer Institute (NCI)-funded clinical trials system more viable and productive. That workshop included...
Dual Awards Pay Tribute to Gender Equity Trailblazers
The University of Texas MD Anderson Cancer Center in Houston recently recognized two leading advocates for women in medicine and research. Karen Antman, MD, Provost of the Boston University Medical Campus and Dean of its School of Medicine since 2005, was the recipient of the 2013 Margaret L....
Indiana University Researchers Earn $3.2 Million Grant to Develop, Improve Therapies for Pancreatic Cancer
Two Indiana University researchers have been awarded a multiyear, $3.2 million grant to develop and improve therapies for pancreatic cancer, the fourth leading cause of cancer death in the United States. Mark R. Kelley, PhD, Betty and Earl Herr Professor of Pediatric Oncology Research, and Melissa...
C. Everett Koop, MD, Surgeon General Under Ronald Reagan, Dies at 96
Appointed by the President and called “America’s Doctor,” the Surgeon General’s chief task is to protect and advance the health of the nation. Most of our Surgeon Generals have tiptoed around hot-button public health issues that might bruise political sensibilities and their own careers. C....
ASCO’s State Oncology Societies Booth Provides a Place for Relationship Building and Sharing Best Practices
Want to learn how to best lobby your local state legislators on the issues that affect your practice in your state? Or finally meet the executive director of your state’s oncology society? Look for the State Oncology Societies Booth at ASCO’s Annual Meeting this year. The booth will be located in...
Gene Transfer Therapy Is Producing Prolonged Remissions in Patients with Advanced Leukemia
In August 2011, researchers from the University of Pennsylvania published their breakthrough findings of a pilot study showing sustained remissions of up to 1 year in a small number of patients with advanced chronic lymphocytic leukemia (CLL) who had been treated with genetically engineered...
Similar Outcomes for 18 vs 36 Months of Androgen Blockade in High-risk Prostate Cancer Treated with Radiation
Eighteen months of hormone therapy appears to be as safe and effective as 36 months when combined with radiation for patients with high-risk prostate cancer.1 Patients who received the shorter course of hormone therapy plus radiation had survival rates similar to those who received 36 months of...
CT Colonography Reconsidered
The parallel SIGGAR trials recently published in Lancet add to the growing body of literature regarding the utility of computed tomographic (CT) colonography in the detection of colorectal polyps and cancers. These papers reinforce the results seen in other large multicenter trials1-3 and echo the...
SIGGAR Trials Compare CT Colonography vs Barium Enema and Colonoscopy in Evaluation for Colon Cancer
The companion UK Special Interest Group in Gastrointestinal and Abdominal Radiology (SIGGAR) trials compared computed tomographic (CT) colonography with barium enema and colonoscopy in patients with symptoms suggestive of colon cancer. As recently reported by the SIGGAR investigators in The...
NCCN Adds Two New Member Institutions
The National Comprehensive Cancer Network (NCCN) recently announced the addition of two new NCCN Member Institutions: UC San Diego Moores Cancer Center in La Jolla, California, and the University of Colorado Cancer Center in Aurora, Colorado. “We are extremely pleased that UC San Diego Moores...
Ado-Trastuzumab Emtansine in Metastatic Breast Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On February 22, 2013, ado-trastuzumab emtansine...
SIDEBAR: Two Caveats on the PCOS Follow-up
Dr. Resnick and colleagues are to be congratulated for following men on the PCOS study out to 15 years. The main result—“At 15 years, no significant relative differences in disease-specific functional outcomes were observed among men undergoing prostatectomy or radiotherapy”—should be interpreted...
Similar 15-year Functional Outcomes after Prostatectomy or Radiotherapy for Localized Prostate Cancer
Comparative longer-term functional outcomes of radical prostatectomy and external-beam radiation therapy for localized prostate cancer remain undefined. In a study recently reported in The New England Journal of Medicine,1 Matthew J. Resnick, MD, and colleagues at Vanderbilt University, Nashville,...
FDA Approves New Radioactive Diagnostic Imaging Agent to Help Locate Lymph Nodes in Patients with Certain Cancers
The FDA has approved technetium Tc 99m tilmanocept (Lymphoseek Injection), a radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing surgery to remove tumor-draining lymph nodes. Tilmanocept is an imaging drug that...
BRAF Mutations in Colorectal Cancer: The Next Frontier
Some 5% to 10% of patients with colorectal cancer harbor the BRAF mutation, placing them at risk for poor treatment response and worse outcomes. The ASCO Post interviewed S. Gail Eckhardt, MD, an expert in this area who is Professor and Head of the Division of Medical Oncology at the University of...
